GeneDx Reports First Quarter 2024 Financial Results and Business Highlights
29 avr. 2024 16h05 HE
|
GeneDx Holdings Corp.
GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the first quarter of 2024.
GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
23 avr. 2024 08h30 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with...
GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024
04 avr. 2024 16h05 HE
|
GeneDx Holdings Corp.
Management will host a conference call on Monday, April 29, 2024 to discuss first quarter 2024 financial and operating results at 4:30 p.m. Eastern Time.
GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics
14 mars 2024 08h30 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at...
GeneDx to Participate in 44th Annual Cowen Health Care Conference
26 févr. 2024 16h05 HE
|
GeneDx Holdings Corp.
GeneDx (Nasdaq: WGS) today announced that company management will participate in the Cowen Healthcare Conference from March 4-6 in Boston, MA.
GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024
20 févr. 2024 16h26 HE
|
GeneDx Holdings Corp.
GeneDx Holdings Corp. (Nasdaq: WGS) reported its financial results for the fourth quarter and full year of 2023.
GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024
01 févr. 2024 16h30 HE
|
GeneDx Holdings Corp.
GeneDx management will host a conference call at 4:30 p.m. Eastern Time on February 20, 2024 to discuss 2023 results and share full year 2024 guidance.
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 janv. 2024 16h30 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Jan. 24, 2024 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of January 23,...
GeneDx Announces Preliminary 2023 Financial Results
08 janv. 2024 08h55 HE
|
GeneDx Holdings Corp.
Expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations of more than $57M.
GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy
01 déc. 2023 08h30 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Dec. 01, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced new data to be...